Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 1NCT07859007A Study to Assess the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics (PK) of Midazolam in Healthy ParticipantsInsmed Incorporated · Healthy VolunteersNot yet recruitingINSMLead
- Enrollment
- Locked
- Primary completion
- Nov 25, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07928037A Study of Real-world Effectiveness of 177Lu-PSMA-617 With and Without Concurrent Androgen Receptor Pathway Inhibitors in Metastatic...Novartis Pharmaceuticals · Metastatic Castration-Resistant Prostate CancerNot yet recruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Nov 25, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT06923891An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia PatientsVanguard Research Group · SchizophreniaNot yet recruitingBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Oct 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06202339Alpha Radiation Emitters Device for the Treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva (DaRT).Alpha Tau Medical LTD. · Carcinoma of the VulvaNot yet recruitingDRTSLead
- Enrollment
- Locked
- Primary completion
- Apr 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06442644Live Music in the Intensive Care UnitAarhus University Hospital · StressNot yet recruitingNVOCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2025Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06669637Amplify EP RegistryHeart Rhythm Clinical and Research Solutions, LLC · Atrial FibrillationNot yet recruitingABTCollaborator
- Enrollment
- Locked
- Primary completion
- May 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06911775Eosinophil Subpopulations in Eosinophilic-associated DiseasesUniversity of Florence · Eosinophilic AsthmaNot yet recruitingGSKCollaborator
- Enrollment
- Locked
- Primary completion
- Jul 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07163481A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic...Hunan Cancer Hospital · Stage IV (Metastatic) Breast CancerNot yet recruitingGILDCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07336654Circadian Rhythm Monitoring StudyResMed · Circadian RhythmNot yet recruitingRMDLead
- Enrollment
- Locked
- Primary completion
- Oct 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT05298293Electronic MonitorIng of Events for dIffuse Large b Cell LYmphomaWeprom · Diffuse Large B Cell LymphomaNot yet recruitingINCYCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06539052MIGrant Reflex Test HDV (MIGRED) ProjectUniversity of Campania Luigi Vanvitelli · Hepatitis D Virus InfectionNot yet recruitingGILDCollaborator
- Enrollment
- Locked
- Primary completion
- Jun 20, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT07055295Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis RegimenSinovac Biotech Co., Ltd · RabiesNot yet recruitingSVALead
- Enrollment
- Locked
- Primary completion
- Dec 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07914972Treatment Pattern and Patient Outcomes Among Stage I-II Unresected NSCLC PatientsAstraZeneca · Non-small Cell Lung CancerNot yet recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Dec 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07915947LTG-321 - Itraconazole Drug-drug Interaction (DDI) StudyLatigo Biotherapeutics · PK Drug-drug Interaction StudyNot yet recruitingLTGOLead
- Enrollment
- Locked
- Primary completion
- Dec 24, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT05778097Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Prostate CancerNot yet recruitingJNJCollaborator
- Enrollment
- Locked
- Primary completion
- Aug 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06635421The Expand Study-Pharmacist Administered Long Acting Cabotegravir + Rilpivirine to Expand Access for People With HIVMetroHealth Medical Center · HIV I InfectionNot yet recruitingGSKCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06702345Clostridioides Difficile Controlled Human Infection ModelLeiden University Medical Center · C. DifficileNot yet recruitingGSKCollaborator
- Enrollment
- Locked
- Primary completion
- Jul 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06797310Evaluating the Effectiveness and Tolerance of Baricitinib in the Treatment of Acute Alopecia Areata With Active Hair Shedding: A...National Taiwan University Hospital · Alopecia AreataNot yet recruitingLLYCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2025Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT06830668Same-Day Restart of B/F/TAF in HIV Patients After NNRTI DiscontinuationNational Center for AIDS/STD Control and Prevention, China CDC · HIV InfectionNot yet recruitingGILDCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07309887This Clinical Trial is a Retrospective, Multicenter Cohort Study Evaluating the Real-world Characteristics and Risk of Disease...Samsung Medical Center · Early Breast CancerNot yet recruitingNVSCollaborator
- Enrollment
- Locked
- Primary completion
- Jan 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07680907A Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm)Janssen-Cilag Farmaceutica Ltda. · Carcinoma, Non-Small-Cell LungNot yet recruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07430059Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide ImplantVivani Medical, Inc · Obesity & OverweightNot yet recruitingVANILead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07945548A Study Characterizing the Elevated Liver Enzymes in Ribociclib Treated HR+ HER2- Advanced Breast Cancer Patients Using a Machine...Novartis Pharmaceuticals · Breast CancerNot yet recruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Jan 1, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07770074A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) PatientsNovartis Pharmaceuticals · Radioiodine-refractory Differentiated Thyroid CancerNot yet recruitingNVSLead
- Enrollment
- Locked
- Primary completion
- Jan 5, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1NCT07908641Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release...Amgen · PsoriasisNot yet recruitingAMGNLead
- Enrollment
- Locked
- Primary completion
- Jan 10, 2027Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 16 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.